AIVITA Doses First 10 Ovarian Cancer Patients with Cell-based Immunotherapy in Phase 2 Trial
News
The Phase 2 clinical trial evaluating AIVITA Biomedical’s cell-based immunotherapy for treating newly-diagnosed advanced ovarian cancer has dosed its first 10 patients. The study (NCT02033616) is looking to enroll 99 women at ... Read more